Skip to content

Efficacy of Protein Supplemented Very Low Calorie Meals on Weight Loss

The Role of Protein Supplemented Very Low Calorie Medical Meals on Weight and Metabolic Changes Among People With Obesity: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04597788
Enrollment
104
Registered
2020-10-22
Start date
2020-11-16
Completion date
2023-01-31
Last updated
2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Sarcopenic Obesity

Brief summary

This randomized clinical trial will evaluate the efficacy and safety of protein supplemented very low calorie meals on weight loss and weight loss maintenance among people with obesity.

Detailed description

Approximately 30% of the Korean population has obesity or abdominal obesity and is often accompanied by obesity related complications such as cardiovascular disease, diabetes, osteoarthritis and even some types of cancer. However, there are not many lifestyle modification treatments available that have long-term effects other than drugs and surgical treatments in the management of obesity. Preserving muscle mass should also be considered in weight loss especially for elderly adults with obesity, because decreased muscle mass and strength can negatively affect morbidity and mortality in the elderly. Therefore, the investigators want to evaluate the effectiveness and safety of the protein supplemented very low calorie meals on weight loss, body composition as well as metabolic changes compared with traditional low calorie low fat diet in people with obesity.

Interventions

OTHERProtein supplemented very low calorie diet program

Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement. Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss.

OTHERConventional low calorie diet program

Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.

Sponsors

Seoul National University Bundang Hospital
CollaboratorOTHER
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Body Mass Index (BMI ) more than 25 kg/m2 or * Waist circumference more than 90 cm in men or 85 cm in women

Exclusion criteria

* History of treatment with anti-obesity drugs or participation in another weight loss program in previous 6 months * Weight changes more than 3 kg during the 6 months before participation * Unstable cardiovascular events during the 6 months before participation * Uncontrolled mood disorder * History of eating disorder * History of alcohol use disorder * History of gallstone * Chronic renal failure (estimated glomerular filtration less than 30 ml/min)

Design outcomes

Primary

MeasureTime frameDescription
Changes in weight12 monthsChanges of weight loss from the baseline expressed as kg

Secondary

MeasureTime frameDescription
Changes in systolic and diastolic blood pressure12 monthsChanges in systolic and diastolic blood pressure from the baseline expressed as mmHg
Changes in triglyceride12 monthsChanges in triglyceride from the baseline expressed as mg/dL
Changes in glucose12 monthsChanges in glucose from the baseline expressed as mg/dL
Changes in high density lipoprotein (HDL) Cholesterol12 monthsChanges in HDL cholesterol from the baseline expressed as mg/dL
Changes in body composition12 monthsChanges in muscle mass and fat mass from the baseline expressed as kg using bioelectrial impedance analysis (Inbody Co., Seoul, Korea)
Changes in liver enzyme12 monthsChanges in aspartate and alanine aminotransferase, gamma glutamyltransferase (AST and ALT, GGT) from the baseline expressed as IU/L
Changes in insulin resistance12 monthsChanges in insulin resistance using the homeostatic model assessment for insulin resistance (HOMA-IR) as HOMA-IR =insulin(uIU/ml) \* fasting glucose (mg/dL)\*0.05551/22.5
Changes in obesity related quality of life12 monthsChanges in Korean version of obesity related quality of life scales (published in Korean Society for the Study of Obesity 2003;12(4):280-293 )
Changes in low density lipoprotein (LDL) Cholesterol12 monthsChanges in LDL cholesterol from the baseline expressed as mg/dL

Countries

South Korea

Contacts

Primary ContactJu Young Kim, MD, PhD
kkamduri@snubh.org(82)1036964218

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026